Business Context and Reporting Period
Company: Standard BioTools Inc. (Nasdaq: LAB)
Filing Type: Form 8-K (Current Report)
Date of Report: January 30, 2026
Event: Completion of the sale of the Company's aptamer-based and functional proteomics business (SomaLogic, Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd) to Illumina, Inc.
Key Financial Metrics and Transaction Details
- Total Consideration: Up to $425 million in aggregate cash.
- Upfront Payment: $350 million paid at closing (subject to customary post-closing adjustments).
- Earnout Potential: Up to $75 million contingent on net revenue targets for SomaScan assay services and SOMAmer-based kits in fiscal years 2025 and 2026.
- Additional Consideration:
- Royalty stream on net revenues from SOMAmer-based next-generation sequencing library preparation kits.
- License for Single SOMAmer intellectual property.
- Royalty stream on net revenues from Single SOMAmers.
- Retained Businesses: Mass cytometry and microfluidics businesses remain with Standard BioTools.
- Financial Statements: Pro forma financial information is not included in this filing and will be filed by amendment within four business days.
Material Changes Versus Prior Period
The filing does not provide comparative revenue, profit, or cash flow metrics for the current period versus the prior period. The primary material change is the divestiture of the SomaLogic/Sengenics entities, resulting in:
- Cessation of the Company's participation in the Collaboration Agreement with Illumina Cambridge, Ltd. (dated December 31, 2021), meaning the Company will no longer receive royalties or payments under that specific agreement.
- Establishment of a Transition Services Agreement where Standard BioTools will provide services to Illumina for a specified period.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Commentary: The Company expects to realize benefits from the transaction, including cash inflows and ongoing royalty streams. Management notes that financial results referenced in the associated press release are unaudited and subject to adjustment.
Risks and Contingencies:
- Earnout Uncertainty: The $75 million earnout is contingent on achieving specific revenue targets in fiscal years 2025 and 2026.
- Integration and Transition: Risks include disruption to operations, loss of customers/suppliers/employees, and management distraction.
- Cost and Cash Usage: Potential for internal/external costs to exceed expectations, accelerating cash usage.
- External Factors: Risks related to NIH funding pressures, U.S. export controls, tariffs, supply chain interruptions, and macroeconomic conditions (inflation/recession).
- Legal: Potential for stockholder litigation regarding the transaction.
Investor Verification Checklist
- Verify the final adjusted amount of the $350 million upfront payment after customary post-closing adjustments.
- Review the upcoming amendment to this 8-K for pro forma financial information to understand the impact on the balance sheet and liquidity.
- Monitor the specific revenue targets required to trigger the $75 million earnout payments for fiscal years 2025 and 2026.
- Assess the terms of the new royalty agreements and the Single SOMAmer license to evaluate future recurring revenue potential.
- Confirm the duration and scope of the Transition Services Agreement to estimate ongoing operational costs or revenue from services provided to Illumina.